Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Provided By GlobeNewswire
Last update: Dec 11, 2024
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug, ATRN-119, over a 24-hour daily cycle
Read more at globenewswire.comNASDAQ:APRE (7/29/2025, 4:30:00 PM)
1.76
-0.12 (-6.38%)
Find more stocks in the Stock Screener
